» Articles » PMID: 35316977

The Innate Immune Response, Microenvironment Proteinases, and the COVID-19 Pandemic: Pathophysiologic Mechanisms and Emerging Therapeutic Targets

Overview
Publisher Elsevier
Specialty Nephrology
Date 2022 Mar 23
PMID 35316977
Authors
Affiliations
Soon will be listed here.
Abstract

The coronavirus disease 2019 (COVID-19) pandemic, causing considerable mortality and morbidity worldwide, has fully engaged the biomedical community in attempts to elucidate the pathophysiology of COVID-19 and develop robust therapeutic strategies. To this end, the predominant research focus has been on the adaptive immune response to COVID-19 infections stimulated by mRNA and protein vaccines and on the duration and persistence of immune protection. In contrast, the role of the innate immune response to the viral challenge has been underrepresented. This overview focuses on the innate immune response to COVID-19 infection, with an emphasis on the roles of extracellular proteases in the tissue microenvironment. Proteinase-mediated signaling caused by enzymes in the extracellular microenvironment occurs upstream of the increased production of inflammatory cytokines that mediate COVID-19 pathology. These enzymes include the coagulation cascade, kinin-generating plasma kallikrein, and the complement system, as well as angiotensin-generating proteinases of the renin-angiotensin system. Furthermore, in the context of several articles in this Supplement elucidating and detailing the trajectory of diverse profibrotic pathways, we extrapolate these insights to explore how fibrosis and profibrotic pathways participate importantly in the pathogenesis of COVID-19. We propose that the lessons garnered from understanding the roles of microenvironment proteinases in triggering the innate immune response to COVID-19 pathology will identify potential therapeutic targets and inform approaches to the clinical management of COVID-19. Furthermore, the information may also provide a template for understanding the determinants of COVID-19-induced tissue fibrosis that may follow resolution of acute infection (so-called "long COVID"), which represents a major new challenge to our healthcare systems.

Citing Articles

COVID-19-Related Spinal Subdural Hematoma Presented with Acute Compressive Myelopathy with a Review of the Literature.

Al-Khalidi H, Hassoun H, Aljid Z, Allebban Z Case Rep Neurol. 2024; 16(1):294-303.

PMID: 39619892 PMC: 11606623. DOI: 10.1159/000528310.


Blood Profiling of Athletes after COVID-19: Differences in Blood Profiles of Post-COVID-19 Athletes Compared to Uninfected Athletic Individuals-An Exploratory Analysis.

Vollrath S, Matits L, Jerg A, Zorn J, John L, Steinacker J Biomedicines. 2023; 11(7).

PMID: 37509550 PMC: 10377547. DOI: 10.3390/biomedicines11071911.


Pathways of Coagulopathy and Inflammatory Response in SARS-CoV-2 Infection among Type 2 Diabetic Patients.

Akacsos-Szasz O, Pal S, Nyulas K, Nemes-Nagy E, Farr A, Denes L Int J Mol Sci. 2023; 24(5).

PMID: 36901751 PMC: 10001503. DOI: 10.3390/ijms24054319.


Probiotics Mechanism of Action on Immune Cells and Beneficial Effects on Human Health.

Mazziotta C, Tognon M, Martini F, Torreggiani E, Rotondo J Cells. 2023; 12(1).

PMID: 36611977 PMC: 9818925. DOI: 10.3390/cells12010184.


The impact of cancer on the severity of disease in patients affected with COVID-19: an umbrella review and meta-meta-analysis of systematic reviews and meta-analyses involving 1,064,476 participants.

Arayici M, Basbinar Y, Ellidokuz H Clin Exp Med. 2022; 23(6):2221-2229.

PMID: 36207550 PMC: 9543928. DOI: 10.1007/s10238-022-00911-3.


References
1.
Han E, MacFarlane R, Mulligan A, Scafidi J, Davis 3rd A . Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest. 2002; 109(8):1057-63. PMC: 150945. DOI: 10.1172/JCI14211. View

2.
Tabacof L, Tosto-Mancuso J, Wood J, Cortes M, Kontorovich A, Mccarthy D . Post-acute COVID-19 Syndrome Negatively Impacts Physical Function, Cognitive Function, Health-Related Quality of Life, and Participation. Am J Phys Med Rehabil. 2021; 101(1):48-52. PMC: 8667685. DOI: 10.1097/PHM.0000000000001910. View

3.
Hashikabe Y, Suzuki K, Jojima T, Uchida K, Hattori Y . Aldosterone impairs vascular endothelial cell function. J Cardiovasc Pharmacol. 2006; 47(4):609-13. DOI: 10.1097/01.fjc.0000211738.63207.c3. View

4.
Bauersachs J, Lother A . Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney Int Suppl (2011). 2022; 12(1):19-26. PMC: 9073241. DOI: 10.1016/j.kisu.2021.11.001. View

5.
Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J . Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020; 24(1):108. PMC: 7081524. DOI: 10.1186/s13054-020-2833-7. View